Biotech Turnaround: How Moderna Went From Revenue Collapse to YTD Rally Leader

"Moderna Inc ( NASDAQ:MRNA) has delivered a 37% gain year-to-date, dramatically outpacing the biotech sector's 0.4% YTD return. In fact, Moderna has the 12th-best gains in the entire S&P 500 so far in 2026! The rally reflects strategic wins and pipeline progress, though recent regulatory turbulence has tested investor conviction. Let's dive into why Moderna is one of the market's biggest winners so far this year."

"Moderna's fourth quarter 2025 results, filed via 8-K in January 2026, showed the company executing on its cost-cutting roadmap. CEO Stéphane Bancel emphasized the operational shift: "strengthened commercial execution, successfully launched third product, reduced annual operating expenses by approximately $2 billion." That expense reduction is an important metric for investors to track because cost-cutting was necessary. The company burned through $4.5 billion in R&D during 2024 while revenue collapsed 53% year-over-year to $3.2 billion."

"On February 10, 2026, Moderna announced a five-year agreement with the Mexican government, BIRMEX, and Laboratorios Liomont. The deal includes technology transfer for domestic COVID-19 vaccine production and supply commitments for Moderna's respiratory vaccine portfolio. This represents a revenue bridge beyond the U.S. market, where COVID vaccine demand has normalized. The partnership supports Mexico's "Plan Mexico" initiative for local mRNA manufacturing infrastructure. The February 6 Recordati collaboration delivered $50 million upfront for mRNA-3927, targeting propionic acidemia. With up to $110 million in nea"

Moderna stock rose 37% year-to-date in 2026, far outpacing the biotech sector's 0.4% return and ranking as the 12th-best performer in the S&P 500. Fourth-quarter 2025 results reflected execution on a cost-cutting roadmap and an announced reduction of approximately $2 billion in annual operating expenses. The company burned $4.5 billion in R&D during 2024 while revenue fell 53% to $3.2 billion. Third-quarter 2025 revenue of $1.02 billion beat estimates and posted a smaller-than-expected loss, triggering a 43% stock recovery from November to mid-January. A five-year Mexican manufacturing and supply agreement and a $50 million upfront collaboration for mRNA-3927 diversify commercialization and revenue pathways amid regulatory turbulence.

Read at 24/7 Wall St.